ERBB2 and neoplasm: Disitamab Vedotin exerts its anti-tumor effects through two main pathways: firstly, by inhibiting downstream signaling pathways activated by HER2, thereby interfering with cell transcription, growth, and proliferation; secondly, by interfering with microtubule formation through the small molecule MMAE, which mainly results in cell cycle arrest.